The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong

Abstract Introduction In Hong Kong (HK), a single-cohort vaccination program for 10–12-year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types 6/11/16/18/31/33/45/52/58) has been launched. This study assessed the public health impact and cost-effectiveness of implementing r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tak Hong Cheung, Sally Shuk Yee Cheng, Danny C. Hsu, Queenie Wing-Lei Wong, Andrew Pavelyev, Anuj Walia, Kunal Saxena, Vimalanand S. Prabhu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Cervical cancer Cost-effectiveness Genital warts Hong Kong Human papillomavirus Vaccine Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/7caf4f54d654497b8b5e3ccef3a85dd4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7caf4f54d654497b8b5e3ccef3a85dd4
record_format	dspace
spelling	oai:doaj.org-article:7caf4f54d654497b8b5e3ccef3a85dd42021-11-21T12:30:43ZThe impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong10.1186/s12962-021-00328-x1478-7547https://doaj.org/article/7caf4f54d654497b8b5e3ccef3a85dd42021-11-01T00:00:00Zhttps://doi.org/10.1186/s12962-021-00328-xhttps://doaj.org/toc/1478-7547Abstract Introduction In Hong Kong (HK), a single-cohort vaccination program for 10–12-year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types 6/11/16/18/31/33/45/52/58) has been launched. This study assessed the public health impact and cost-effectiveness of implementing routine 9vHPV vaccination (12-year-olds) with or without catch-up 9vHPV vaccination (13–18-year-olds) in HK. Methods The health impact and costs of implementing routine 9vHPV vaccination with or without catch-up vaccination over a 100-year time horizon were evaluated using a validated HPV-type transmission dynamic model adapted to the HK population; analyses were performed from a healthcare payer perspective. Routine vaccination (12-year-old girls) and catch-up vaccination (13–18 years) assumed vaccine coverage rates of 70% (base case) and 30%, respectively. The model also assumed herd immunity, lifelong vaccine protection, a discount rate of 3%, and a cost per dose of HK dollars (HKD) 858 [United States dollars (USD) 110] and HKD 1390 (USD 179) for the 2-valent HPV (2vHPV) and 9vHPV vaccines, respectively. HPV disease-related incidence and the incremental cost-effectiveness ratio (ICER) per quality-adjusted-life-year (QALY) were estimated. Cost-effectiveness was determined at a ceiling threshold of HK dollars (HKD) 382,046 (USD 49,142) or 1.0 times the gross domestic product per capita of HK. Results Compared with routine 9vHPV alone, routine plus catch-up 9vHPV is projected to reduce cervical cancer incidence by 3.4%. Routine plus catch-up 9vHPV will also reduce genital warts incident cases for males/females by 2.6%/5.4%. The incremental cost-effectiveness ratios were HKD 29,911 (USD 3847)/quality-adjusted life-year (QALY) for routine plus catch-up 9vHPV versus routine 9vHPV alone and HKD 25,524 (USD 3283)/QALY for routine 9vHPV alone versus screening only. Sensitivity analyses indicated that routine plus catch-up 9vHPV compared with routine 9vHPV alone remained cost-effective at coverage rates of 30% and 90%. Conclusions This analysis predicts that the current HK vaccination strategy can be considered cost-effective and will provide maximum health benefit. These results support addition of the routine 9vHPV vaccine with or without catch-up 9vHPV vaccination to the regional vaccination program in HK.Tak Hong CheungSally Shuk Yee ChengDanny C. HsuQueenie Wing-Lei WongAndrew PavelyevAnuj WaliaKunal SaxenaVimalanand S. PrabhuBMCarticleCervical cancerCost-effectivenessGenital wartsHong KongHuman papillomavirusVaccineMedicine (General)R5-920ENCost Effectiveness and Resource Allocation, Vol 19, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cervical cancer Cost-effectiveness Genital warts Hong Kong Human papillomavirus Vaccine Medicine (General) R5-920
spellingShingle	Cervical cancer Cost-effectiveness Genital warts Hong Kong Human papillomavirus Vaccine Medicine (General) R5-920 Tak Hong Cheung Sally Shuk Yee Cheng Danny C. Hsu Queenie Wing-Lei Wong Andrew Pavelyev Anuj Walia Kunal Saxena Vimalanand S. Prabhu The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
description	Abstract Introduction In Hong Kong (HK), a single-cohort vaccination program for 10–12-year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types 6/11/16/18/31/33/45/52/58) has been launched. This study assessed the public health impact and cost-effectiveness of implementing routine 9vHPV vaccination (12-year-olds) with or without catch-up 9vHPV vaccination (13–18-year-olds) in HK. Methods The health impact and costs of implementing routine 9vHPV vaccination with or without catch-up vaccination over a 100-year time horizon were evaluated using a validated HPV-type transmission dynamic model adapted to the HK population; analyses were performed from a healthcare payer perspective. Routine vaccination (12-year-old girls) and catch-up vaccination (13–18 years) assumed vaccine coverage rates of 70% (base case) and 30%, respectively. The model also assumed herd immunity, lifelong vaccine protection, a discount rate of 3%, and a cost per dose of HK dollars (HKD) 858 [United States dollars (USD) 110] and HKD 1390 (USD 179) for the 2-valent HPV (2vHPV) and 9vHPV vaccines, respectively. HPV disease-related incidence and the incremental cost-effectiveness ratio (ICER) per quality-adjusted-life-year (QALY) were estimated. Cost-effectiveness was determined at a ceiling threshold of HK dollars (HKD) 382,046 (USD 49,142) or 1.0 times the gross domestic product per capita of HK. Results Compared with routine 9vHPV alone, routine plus catch-up 9vHPV is projected to reduce cervical cancer incidence by 3.4%. Routine plus catch-up 9vHPV will also reduce genital warts incident cases for males/females by 2.6%/5.4%. The incremental cost-effectiveness ratios were HKD 29,911 (USD 3847)/quality-adjusted life-year (QALY) for routine plus catch-up 9vHPV versus routine 9vHPV alone and HKD 25,524 (USD 3283)/QALY for routine 9vHPV alone versus screening only. Sensitivity analyses indicated that routine plus catch-up 9vHPV compared with routine 9vHPV alone remained cost-effective at coverage rates of 30% and 90%. Conclusions This analysis predicts that the current HK vaccination strategy can be considered cost-effective and will provide maximum health benefit. These results support addition of the routine 9vHPV vaccine with or without catch-up 9vHPV vaccination to the regional vaccination program in HK.
format	article
author	Tak Hong Cheung Sally Shuk Yee Cheng Danny C. Hsu Queenie Wing-Lei Wong Andrew Pavelyev Anuj Walia Kunal Saxena Vimalanand S. Prabhu
author_facet	Tak Hong Cheung Sally Shuk Yee Cheng Danny C. Hsu Queenie Wing-Lei Wong Andrew Pavelyev Anuj Walia Kunal Saxena Vimalanand S. Prabhu
author_sort	Tak Hong Cheung
title	The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
title_short	The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
title_full	The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
title_fullStr	The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
title_full_unstemmed	The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
title_sort	impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in hong kong
publisher	BMC
publishDate	2021
url	https://doaj.org/article/7caf4f54d654497b8b5e3ccef3a85dd4
work_keys_str_mv	AT takhongcheung theimpactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT sallyshukyeecheng theimpactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT dannychsu theimpactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT queeniewingleiwong theimpactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT andrewpavelyev theimpactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT anujwalia theimpactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT kunalsaxena theimpactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT vimalanandsprabhu theimpactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT takhongcheung impactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT sallyshukyeecheng impactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT dannychsu impactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT queeniewingleiwong impactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT andrewpavelyev impactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT anujwalia impactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT kunalsaxena impactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong AT vimalanandsprabhu impactandcosteffectivenessof9valenthumanpapillomavirusvaccineinadolescentfemalesinhongkong
_version_	1718418954064494592

The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong

Ejemplares similares